Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours

被引：0
|
作者：
S. A. Veltkamp
H. Rosing
A. D. R. Huitema
M. R. Fetell
A. Nol
J. H. Beijnen
J. H. M. Schellens
机构：
[1] The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,Division of Experimental Therapy
[2] The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital,Department of Medical Oncology
[3] The Netherlands Cancer Institute/Slotervaart Hospital,Department of Pharmacy and Pharmacology
[4] University of Utrecht,Division of Biomedical Analysis, Faculty of Pharmaceutical Sciences
[5] Ivax Research,undefined
[6] Inc.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2007年 / 60卷
关键词：
Phase I; Pharmacokinetics; Paclitaxel; Cremophor-free; Oral administration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：635 / 642
页数：7
相关论文
共 50 条
  • [31] Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol®-PM) in patients with solid tumors
    Lim, W. T.
    Tan, E. H.
    Toh, C. K.
    Hee, S. W.
    Leong, S. S.
    Ang, P. C. S.
    Wong, N. S.
    Chowbay, B.
    ANNALS OF ONCOLOGY, 2010, 21 (02) : 382 - 388
  • [32] A phase I pharmacokinetic study of a liposomal formulation of paclitaxel administered weekly to Asian patients with solid malignancies
    Lim, W. T.
    Leong, S. S.
    Toh, C. K.
    Ang, C. S.
    Wong, N. S.
    Tan, E. H.
    Chowbay, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers
    Chon, Hye Sook
    Kang, Sokbom
    Lee, Jae K.
    Apte, Sachin M.
    Shahzad, Mian M.
    Williams-Elson, Irene
    Wenham, Robert M.
    BMC CANCER, 2017, 17
  • [34] Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers
    Hye Sook Chon
    Sokbom Kang
    Jae K. Lee
    Sachin M. Apte
    Mian M. Shahzad
    Irene Williams-Elson
    Robert M. Wenham
    BMC Cancer, 17
  • [35] Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid cancers.
    Chon, Hye Sook
    Apte, Sachin M.
    Shahzad, Mian M.
    Williams-Elson, Irene
    Kang, Sokbum
    Lee, Jae K.
    Wenham, Robert Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [36] A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
    Richard H Wilson
    TR Jeffry Evans
    Mark R Middleton
    L Rhoda Molife
    James Spicer
    Veronique Dieras
    Patricia Roxburgh
    Heidi Giordano
    Sarah Jaw-Tsai
    Sandra Goble
    Ruth Plummer
    British Journal of Cancer, 2017, 116 : 884 - 892
  • [37] Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours
    Kerklaan, B. Milojkovic
    Lolkema, M. P. J.
    Devriese, L. A.
    Voest, E. E.
    Nol-Boekel, A.
    Mergui-Roelvink, M.
    Langenberg, M.
    Mykulowycz, K.
    Stoebenau, J.
    Lane, S.
    Legenne, P.
    Wissel, P.
    Smith, D. A.
    Giantonio, B. J.
    Schellens, J. H. M.
    Witteveen, P. O.
    BRITISH JOURNAL OF CANCER, 2015, 113 (05) : 706 - 715
  • [38] A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
    Wilson, Richard H.
    Evans, T. R. Jeffry
    Middleton, Mark R.
    Molife, L. Rhoda
    Spicer, James
    Dieras, Veronique
    Roxburgh, Patricia
    Giordano, Heidi
    Jaw-Tsai, Sarah
    Goble, Sandra
    Plummer, Ruth
    BRITISH JOURNAL OF CANCER, 2017, 116 (07) : 884 - 892
  • [39] Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours
    B Milojkovic Kerklaan
    M P J Lolkema
    L A Devriese
    E E Voest
    A Nol-Boekel
    M Mergui-Roelvink
    M Langenberg
    K Mykulowycz
    J Stoebenau
    S Lane
    P Legenne
    P Wissel
    D A Smith
    B J Giantonio
    J H M Schellens
    P O Witteveen
    British Journal of Cancer, 2015, 113 : 706 - 715
  • [40] Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours
    A R A Razak
    S J Hotte
    L L Siu
    E X Chen
    H W Hirte
    J Powers
    W Walsh
    L-A Stayner
    A Laughlin
    V Novotny-Diermayr
    J Zhu
    E A Eisenhauer
    British Journal of Cancer, 2011, 104 : 756 - 762
12345